Combination therapy for carbapenem-resistant Gram-negative bacteria

Area of Science:

• Infectious Diseases
• Clinical Microbiology
• Pharmacology

Background:

• Carbapenem-resistant Gram-negative bacteria (CR-GNB) pose a significant threat in healthcare.
• Treatment of invasive CR-GNB infections often considers combination antibiotic therapy.
• Potential benefits include synergy, but risks include adverse events and resistance development.

Purpose of the Study:

• To evaluate the current evidence for combination therapy versus monotherapy in treating CR-GNB infections.
• To highlight limitations of existing observational studies.
• To inform clinical practice and guide future research, particularly randomized controlled trials (RCTs).

Main Methods:

• Review and critical analysis of existing observational studies comparing combination therapy to colistin/polymyxin monotherapy for CR-GNB infections.
• Assessment of study designs, sample sizes, and inherent biases.
• Consideration of ongoing and recently completed randomized controlled trials.

Main Results:

• Observational studies comparing combination therapy to colistin/polymyxin monotherapy for CR-GNB infections have significant limitations.
• These limitations, including small sample sizes and observational design, prevent definitive conclusions on the superiority of combination therapy.
• Currently, there is a lack of robust evidence supporting most combination therapies for CR-GNB, including colistin/carbapenem combinations.

Conclusions:

• Existing observational data are insufficient to support the routine use of combination antibiotic therapy for CR-GNB infections.
• Further high-quality randomized controlled trials are essential to establish evidence-based treatment guidelines.
• Clinical decisions should be guided by the current lack of evidence until definitive trial results are available.